We examined the effects of the mitochondria-targeted antioxidant MitoQ on disease progression in a mouse model of ALS.
MitoQ slowed the mitochondrial functional decline in the spinal cord and muscle.
MitoQ decreased nitroxidative damage in the nervous system.
MitoQ treatment increased survival and slowed the progression of ALS symptoms.